[go: up one dir, main page]

ECSP10010289A - Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada - Google Patents

Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada

Info

Publication number
ECSP10010289A
ECSP10010289A EC2010010289A ECSP10010289A ECSP10010289A EC SP10010289 A ECSP10010289 A EC SP10010289A EC 2010010289 A EC2010010289 A EC 2010010289A EC SP10010289 A ECSP10010289 A EC SP10010289A EC SP10010289 A ECSP10010289 A EC SP10010289A
Authority
EC
Ecuador
Prior art keywords
prolonged action
dosage regime
injectable paliperidone
regime associated
paliperidone esters
Prior art date
Application number
EC2010010289A
Other languages
English (en)
Inventor
An Margriet Cornelia Vermeulen
Alfons Jeanne Wouters
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40428256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010289(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP10010289A publication Critical patent/ECSP10010289A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • H—ELECTRICITY
    • H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10F—INORGANIC SEMICONDUCTOR DEVICES SENSITIVE TO INFRARED RADIATION, LIGHT, ELECTROMAGNETIC RADIATION OF SHORTER WAVELENGTH OR CORPUSCULAR RADIATION
    • H10F30/00—Individual radiation-sensitive semiconductor devices in which radiation controls the flow of current through the devices, e.g. photodetectors
    • H10F30/20—Individual radiation-sensitive semiconductor devices in which radiation controls the flow of current through the devices, e.g. photodetectors the devices having potential barriers, e.g. phototransistors
    • H10F30/21—Individual radiation-sensitive semiconductor devices in which radiation controls the flow of current through the devices, e.g. photodetectors the devices having potential barriers, e.g. phototransistors the devices being sensitive to infrared, visible or ultraviolet radiation
    • H10F30/22—Individual radiation-sensitive semiconductor devices in which radiation controls the flow of current through the devices, e.g. photodetectors the devices having potential barriers, e.g. phototransistors the devices being sensitive to infrared, visible or ultraviolet radiation the devices having only one potential barrier, e.g. photodiodes
    • H10F30/222—Individual radiation-sensitive semiconductor devices in which radiation controls the flow of current through the devices, e.g. photodetectors the devices having potential barriers, e.g. phototransistors the devices being sensitive to infrared, visible or ultraviolet radiation the devices having only one potential barrier, e.g. photodiodes the potential barrier being a PN heterojunction
    • H10P95/00—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Manufacturing & Machinery (AREA)
  • Computer Hardware Design (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Power Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona un método para tratar pacientes que necesitan un tratamiento con formulaciones de palmitato de paliperidona inyectable de acción prolongada.
EC2010010289A 2007-12-19 2010-06-18 Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada ECSP10010289A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1491807P 2007-12-19 2007-12-19
US12027608P 2008-12-05 2008-12-05

Publications (1)

Publication Number Publication Date
ECSP10010289A true ECSP10010289A (es) 2010-07-30

Family

ID=40428256

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010289A ECSP10010289A (es) 2007-12-19 2010-06-18 Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada

Country Status (28)

Country Link
US (3) US9439906B2 (es)
EP (2) EP3909585A1 (es)
JP (1) JP5825786B2 (es)
KR (3) KR20100099292A (es)
CN (2) CN101932327A (es)
AU (2) AU2008340101C1 (es)
BR (1) BRPI0821408A2 (es)
CO (1) CO6300949A2 (es)
CY (1) CY1124103T1 (es)
DK (1) DK2234617T4 (es)
EA (1) EA020697B1 (es)
EC (1) ECSP10010289A (es)
ES (1) ES2868353T5 (es)
FI (1) FI2234617T4 (es)
GT (1) GT201000182A (es)
HK (1) HK1223850A1 (es)
HR (1) HRP20210669T4 (es)
HU (1) HUE053904T2 (es)
IL (2) IL206448A (es)
LT (1) LT2234617T (es)
MY (1) MY204500A (es)
NI (1) NI201000105A (es)
NZ (1) NZ586221A (es)
PL (1) PL2234617T3 (es)
PT (1) PT2234617T (es)
RS (1) RS61765B2 (es)
SI (1) SI2234617T2 (es)
WO (1) WO2009080651A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
DK2234617T4 (da) 2007-12-19 2024-12-16 Janssen Pharmaceutica Nv Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
WO2011042450A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Carrier linked paliperidone prodrugs
NZ599558A (en) * 2009-10-30 2014-09-26 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
WO2011114213A1 (en) 2010-03-15 2011-09-22 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
US9522980B2 (en) 2010-05-06 2016-12-20 Johnson & Johnson Vision Care, Inc. Non-reactive, hydrophilic polymers having terminal siloxanes and methods for making and using the same
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
AU2012231160B2 (en) * 2011-03-18 2017-04-06 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
US9170349B2 (en) 2011-05-04 2015-10-27 Johnson & Johnson Vision Care, Inc. Medical devices having homogeneous charge density and methods for making same
PT2529756T (pt) 2011-05-31 2021-07-28 Farm Rovi Lab Sa Formulação de implante de risperidona e/ou paliperidona
ES2456917T3 (es) 2011-05-31 2014-04-24 Laboratorios Farmacéuticos Rovi, S.A. Formulación de implante de paliperidona
CN102274164B (zh) * 2011-08-22 2014-07-02 长春健欣生物医药科技开发有限公司 帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂
CN103301461B (zh) * 2012-03-08 2018-09-07 江苏豪森药业集团有限公司 一种长效注射制剂及其制备方法和用途
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
ES2764383T3 (es) 2012-03-19 2020-06-03 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de glicerol
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US9244196B2 (en) 2012-05-25 2016-01-26 Johnson & Johnson Vision Care, Inc. Polymers and nanogel materials and methods for making and using the same
US10073192B2 (en) 2012-05-25 2018-09-11 Johnson & Johnson Vision Care, Inc. Polymers and nanogel materials and methods for making and using the same
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
CN110368360A (zh) 2014-03-20 2019-10-25 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
US10064859B2 (en) 2014-08-25 2018-09-04 Alkermes Pharma Ireland Limited Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
CN107249586A (zh) 2015-02-17 2017-10-13 万达制药公司 用于治疗精神分裂症的伊潘立酮
WO2016157061A1 (en) 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
JP6728221B2 (ja) * 2015-04-07 2020-07-22 ヤンセン ファーマシューティカルズ，インコーポレーテッド 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン
EP3544593A4 (en) * 2016-11-23 2020-11-25 Children's Hospital Medical Center PALIPERIDONE FOR THE TREATMENT OF DRUG REFRACTORY IRRITABILITY AND AUTISTIC SPECTRUM DISORDER
US11666573B2 (en) 2017-10-27 2023-06-06 Geneora Pharma (Shijiazhuang) Co., Ltd. Dosage regimen of paliperidone palmitate extended-release injectable suspension
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN110279659A (zh) * 2019-07-08 2019-09-27 华裕(无锡)制药有限公司 棕榈酸帕利哌酮制剂及其制备方法
GR1009869B (el) * 2019-07-12 2020-11-12 Φαρματεν Α.Β.Ε.Ε. Ενεσιμο παρατεταμενης αποδεσμευσης φαρμακευτικο σκευασμα που περιλαμβανει παλμιτικη παλιπεριδονη και μεθοδος παρασκευης αυτου
US12431230B2 (en) 2019-09-25 2025-09-30 Janssen Pharmaceuticals, Inc. Interconnection of drug administration systems
WO2022006336A1 (en) * 2020-07-01 2022-01-06 Jubilant Pharma Holdings Inc. Long-acting injection dosage form of beta 3 adrenoreceptor agonists
US11324751B1 (en) 2020-11-30 2022-05-10 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
TW202222317A (zh) 2020-11-30 2022-06-16 比利時商健生藥品公司 與延釋帕利哌酮可注射配製物相關之投藥方案（一）
HRP20240074T1 (hr) * 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem
DK4005555T3 (da) 2020-11-30 2024-05-27 Janssen Pharmaceutica Nv Fremgangsmåder til at sikre resuspension af paliperidonpalmitat-formuleringer
RU2756614C1 (ru) * 2021-04-07 2021-10-04 Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) Способ поддержки принятия врачебных решений выбора антипсихотической терапии у больных шизофренией с целью профилактики акатизии
CN118119394A (zh) 2021-08-20 2024-05-31 詹森药业有限公司 与延长释放帕潘立酮可注射制剂相关的给药方案

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1491807A (en) 1922-06-20 1924-04-29 John P Mclinn Traveling bag
US1491809A (en) 1923-02-17 1924-04-29 Us Fireworks Mfg Company Inc Toy
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
WO2000010572A1 (en) 1998-08-18 2000-03-02 Sepracor Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
KR100338776B1 (ko) 2000-07-11 2002-05-31 윤종용 멀티 로우 어드레스 테스트 가능한 반도체 메모리 장치 및그 테스트 방법
WO2004010981A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone
AU2003265511A1 (en) 2002-08-21 2004-03-11 Pharmacia Corporation Injectable pharmaceutical suspension in a two-chamber vial
US20060079846A1 (en) 2004-10-08 2006-04-13 Alton Williams Hypodermic syringes with multiple needles and methods of calming psychiatric patients using such
CN101163702B (zh) 2005-04-25 2011-09-07 詹森药业有限公司 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
US20070197591A1 (en) * 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
US20070232624A1 (en) * 2006-04-03 2007-10-04 Palumbo Joseph M Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients
TW200825077A (en) 2006-08-14 2008-06-16 Teva Pharma Crystal forms of 9-hydroxy-risperidone (paliperidone)
HRP20110863T1 (hr) 2007-08-21 2011-12-31 Teva Pharmaceutical Industries Ltd. Oblik produljenog oslobađanja paliperidona
US8242269B2 (en) 2007-10-09 2012-08-14 Cipla Limited Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes
DK2234617T4 (da) 2007-12-19 2024-12-16 Janssen Pharmaceutica Nv Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere
NZ599558A (en) 2009-10-30 2014-09-26 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
US11114549B2 (en) 2017-11-29 2021-09-07 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor structure cutting process and structures formed thereby
US11450758B2 (en) 2020-06-12 2022-09-20 Taiwan Semiconductor Manufacturing Co., Ltd. Gate structure of semiconductor device and method of forming same

Also Published As

Publication number Publication date
US20170128451A1 (en) 2017-05-11
IL206448A0 (en) 2010-12-30
PL2234617T3 (pl) 2021-11-08
EP2234617A1 (en) 2010-10-06
US20180147210A1 (en) 2018-05-31
EP3909585A1 (en) 2021-11-17
JP2011506555A (ja) 2011-03-03
HUE053904T2 (hu) 2021-07-28
EP2234617B1 (en) 2021-03-31
EA201070757A1 (ru) 2011-02-28
IL206448A (en) 2017-12-31
JP5825786B2 (ja) 2015-12-02
ES2868353T3 (es) 2021-10-21
KR102163196B1 (ko) 2020-10-12
IL253468A0 (en) 2017-09-28
CO6300949A2 (es) 2011-07-21
HRP20210669T1 (hr) 2021-10-29
KR20100099292A (ko) 2010-09-10
CN105560176A (zh) 2016-05-11
HK1223850A1 (zh) 2017-08-11
DK2234617T3 (da) 2021-05-25
KR102318070B1 (ko) 2021-10-27
AU2008340101C1 (en) 2025-03-06
SI2234617T2 (sl) 2025-05-30
SI2234617T1 (sl) 2021-07-30
LT2234617T (lt) 2021-05-25
PT2234617T (pt) 2021-05-18
FI2234617T4 (fi) 2024-12-23
GT201000182A (es) 2012-03-26
US9439906B2 (en) 2016-09-13
CN101932327A (zh) 2010-12-29
NZ586221A (en) 2012-08-31
ES2868353T5 (en) 2025-04-02
EP2234617B2 (en) 2024-11-06
EA020697B1 (ru) 2015-01-30
BRPI0821408A2 (pt) 2015-06-16
AU2015200801A1 (en) 2015-03-12
CY1124103T1 (el) 2022-05-27
NI201000105A (es) 2011-03-17
DK2234617T4 (da) 2024-12-16
AU2008340101A1 (en) 2009-07-02
MY204500A (en) 2024-08-30
KR20190049933A (ko) 2019-05-09
RS61765B2 (sr) 2025-01-31
AU2015200801B2 (en) 2016-12-15
RS61765B1 (sr) 2021-05-31
WO2009080651A1 (en) 2009-07-02
KR20170018489A (ko) 2017-02-17
US20090163519A1 (en) 2009-06-25
HRP20210669T4 (hr) 2024-12-06
AU2008340101B2 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
ECSP10010289A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada
CY1122628T1 (el) Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX352328B (es) Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
CY1116424T1 (el) Παραγωγο αδενινης ως αναστολεας ρι3κ
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
UY32487A (es) Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
ECSP15008695A (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
CL2012002424A1 (es) Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende.
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
AR091205A1 (es) Farmaco para prevenir y tratar la enfermedad renal poliquistica
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
CO7121334A2 (es) Formulaciones vesiculares
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
DOP2013000004A (es) Agentes terapeuticos 976
CY1115587T1 (el) Μεθοδος και συνθεση για την θεραπεια παθησης με την μεσολαβηση ενος ληπτη σεροτονινης (sεrοτονιν)
UA99163C2 (ru) Способ дозирования инъекционной формы палиперидона пальмитата продолжительного действия
CY1114276T1 (el) Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας